Industry Gene Therapy Licensing Agreement Between uniQure and CSL Now in EffectMay 7, 2021 Industry uniQure Announces End of Clinical Hold on Hemophilia B Gene Therapy…Apr 27, 2021 Industry uniQure Announces Findings from HCC Case InvestigationMar 30, 2021 Industry Update to Hemlibra® (emicizumab-kxwh) USPIMar 12, 2021 Industry New Program Looks to Standardize Care for Patients with Rare DiseasesMar 2, 2021 Industry FDA Partially Rescinds Added Indications for Two FIX ProductsFeb 23, 2021 Industry Sanofi Revises Fitusiran Dosing Regimen to Mitigate Risk of Vascular…Feb 22, 2021 Industry Spark Announces Preliminary Data from Investigational Gene Therapy TrialFeb 19, 2021 Industry Octapharma Announces Final Results of Nuwiq® StudyFeb 19, 2021 Industry BioMarin Announces Positive Phase 3 Study Data for Valoctocogene…Jan 25, 2021 Industry FDA Puts Clinical Hold on uniQure's Hope B TrialDec 20, 2020 Industry Catalyst Announces New FDA Designation and Phase 3 MarzAA Study Design Dec 7, 2020 Industry Pfizer Announces First Participant Dosed Phase 3 Study of MarstacimabNov 30, 2020 Industry uniQure Announces Positive Results from Phase 3 Gene Therapy TrialNov 20, 2020 Industry Global Dosing Hold in Fitusiran Trials Initiated…Nov 5, 2020 Pagination First page Previous page Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Last page
